Delivery Order SPE2DR25D1200-SPE2DR26FML2Q

<p>The Defense Logistics Agency issued a $4,775.88 delivery order to Amerisourcebergen Drug Corp on February 5, 2026, for HUMIRA(CF) Pen 40 mg/0.4 mls with an ultimate completion date of February 6, 2026.</p> <p>Place of performance is Conshohocken, PA. The order is issued under firm fixed-price pricing with no set-aside applied.</p>

<p>The Defense Logistics Agency issued a $4,807.88 delivery order to Amerisourcebergen Drug Corp on February 5, 2026, for HUMIRA(CF) Pen 40 mg/0.4 mls with an ultimate completion date of February 6, 2026.</p> <p>Place of performance is Conshohocken, PA. The order is firm fixed price with no set-aside applied.</p>

<p>The Defense Logistics Agency issued a $3,244.26 delivery order to Amerisourcebergen Drug Corp on February 5, 2026, for HUMIRA(CF) Pen 40 mg/0.4 mls.</p> <p>Place of performance is Conshohocken, PA. The order has a ceiling value of $3,244.26 with an ultimate completion date of February 6, 2026. Pricing is firm fixed price, and no set-aside was used.</p>

<p>The Defense Logistics Agency issued a delivery order to AmerisourceBergen Drug Corp on February 5, 2026, for HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $5,263.78.</p> <p>Place of performance is Conshohocken, PA. The order carries a firm fixed price and ultimate completion date of February 6, 2026. The delivery order was issued without set-aside.</p>

<p>The Defense Logistics Agency issued a $8,207.64 delivery order to Amerisourcebergen Drug Corp on February 5, 2026, for HUMIRA(CF) Pen 40 mg/0.4 mls with an ultimate completion date of February 6, 2026.</p> <p>Place of performance is Conshohocken, PA. The order is firm fixed price with no set-aside. The source does not identify the parent IDV or IDIQ by name.</p>

The Defense Logistics Agency issued a $16,639.36 delivery order to Amerisourcebergen Drug Corp on February 4, 2026, for HUMIRA(CF) Pen 40 mg/0.4 mL pharmaceutical supply under a firm fixed-price contract with an ultimate completion date of February 5, 2026. Place of performance is Conshohocken, PA. The order carries no set-aside designation and represents a call against the parent Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which...

The Defense Logistics Agency issued a $25,328.26 delivery order to Amerisourcebergen Drug Corp on February 5, 2026, for HUMIRA(CF) Pen 40 mg/0.4 mL pharmaceutical supply. The order is issued under Amerisourcebergen's parent company Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. That IDC provides pharmaceutical products and medical supplies to support military healthcare programs globally. Place of...

<p>The Defense Logistics Agency issued a $6,816.50 delivery order to Amerisourcebergen Drug Corp on February 4, 2026, for HUMIRA(CF) Pen 40 mg/0.4 mls pharmaceutical supply. Place of performance is Conshohocken, PA. The order is issued under a parent Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 and running through December 2026.</p>

Defense Logistics Agency awarded a $3,523.38 firm fixed price delivery order to Amerisourcebergen Drug Corporation for HUMIRA(CF) PEN 40 MG/0.4 MLS. The delivery order was issued against an existing contract vehicle and has a period of performance through October 17, 2023. The place of performance is Conshohocken, Pennsylvania. No set-aside designation was applied to this award to supply the pharmaceutical product from the prime contractor, Amerisourcebergen Drug Corporation, operating from...

Defense Logistics Agency awarded a $1,174.44 firm fixed price delivery order to Amerisourcebergen Drug Corporation for HUMIRA(CF) PEN 80 MG/0.8 MLS. The delivery order was awarded on October 11, 2023 under the prime vendor's corporate office blanket purchase agreement and has an anticipated completion date of October 12, 2023. To be performed in Conshohocken, Pennsylvania, the delivery order utilizes no set-aside designation and is for the provision of the referenced pharmaceutical product to...